Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
New HMBD-002 Data Presented at ASCO Annual Meeting 4 pages 2.0MB
Regulatory Filings
2026-06-02 English
Notification regarding unquoted securities - PER 5 pages 16.9KB
Share Issue/Capital Change Classification · 92% confidence The document is an ASX Appendix 3G notifying the issue of unquoted equity securities, detailing numbers, dates, and transaction background. This is a direct announcement of a new share issue/capital change, fitting the share issue/capital change category.
2026-06-01 English
Proposed issue of securities - PER 5 pages 17.0KB
Share Issue/Capital Change Classification · 90% confidence The document is an ASX Appendix 3B announcement (“Proposed issue of securities”) by Percheron Therapeutics Limited detailing the placement/issue of new securities (options) under ASX Listing Rules. This is a capital raising/shares issuance notice, matching the definition of Share Issue/Capital Change (SHA).
2026-05-28 English
WHO selects proposed INN for HMBD-002 3 pages 143.8KB
Regulatory Filings Classification · 85% confidence The document is an ASX announcement regarding the selection of an international nonproprietary drug name by WHO. It contains no financial data, statements, or detailed report content, nor is it a management report, earnings release, or other specific filing type. It is a general regulatory announcement made to the exchange, fitting the “Regulatory Filings” (RNS) category as a miscellaneous regulatory disclosure.
2026-05-25 English
Notification of cessation of securities - PER 4 pages 14.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of certain securities (options) for Percheron Therapeutics Limited. It provides specific information about the securities that have ceased, reasons for cessation, and updated issued capital figures. The document is a formal announcement related to changes in the company's securities, specifically the cessation of certain options. It does not contain financial statements, management discussion, or other report content. The document length is 3781 characters, which is relatively short and focused on a specific securities cessation event. This fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement about securities status changes that does not fit into more specific categories like capital changes or director dealings. It is not a capital raising or share issue announcement, but a notification of cessation of securities, which is typically filed as a regulatory announcement.
2026-04-30 English
Quarterly Activities Report and Appendix 4C 10 pages 553.0KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' for the quarter ended 31 March 2026. It provides a detailed update on the company's activities during the quarter, including a capital raise, clinical trial progress, conference presentations, and a detailed unaudited quarterly cash flow report (Appendix 4C) with financial data such as cash flows from operating, investing, and financing activities. The presence of substantive financial data and analysis for a period shorter than a full fiscal year, along with operational updates, aligns with the definition of an Interim / Quarterly Report (IR). The document is not merely an announcement of a report but contains the report itself with financial statements and commentary. Therefore, the correct classification is IR (Interim / Quarterly Report). Q1 2026
2026-04-29 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.